Further refinement of the manufacturing process of Leishmania tropica Skin Test Antigen (LtSTA) was made during this contract period to increase the yield and robustness of the parasite during culture. Identity and potency tests for LtSTA were developed and the procedures are being validated. The analysis of dose-response, safety and efficacy data from a phase II clinical trial conducted in Sidi Bouzid, Tunisia in 2007 were compiled and analyzed, and ...
Reports by Author
